title: [Clinical research on transfer of cefpiramide to the blood and large intestinal tissue in patients with cancer of the large bowel].
abstract: Cefpiramide (CPM) shows antibacterial activity against Staphylococci, Enterococci, Pseudomonas aeruginosa and anaerobic Bacteroides spp. CPM is a cephalosporin antibiotic which also exhibits antibacterial activity against Klebsiella and intestinal bacteria including Escherichia coli. Concentrations in blood of CPM which has antibacterial activity against main bacterial species detected during gastrointestinal surgeries and concentration transferred to the large intestinal tissue were measured in patients with cancer of the large intestine. Eighteen patients who were hospitalized and underwent large intestinal surgery from December, 1985 to March, 1987 were examined as subjects. CPM was administered at a dose 1 g each of 11 cases and 2 g to each of 7 cases. Concentrations in blood after administration of 1 g of CPM were in a range of 81.56-212.6 micrograms/ml between 25 minutes and 2 hours 20 minutes after administration, and concentrations in the large intestinal tissue were in a 14.17-66.95 micrograms/g range. Ratios of the tissue to the blood concentrations were 0.08-0.49, averaging 0.24 +/- 0.05. Concentrations in blood after administration of 2 g of CPM were 128.4-253.5 micrograms/ml between 1 hour 10 minutes and 3 hours 50 minutes after administration. Tissue concentrations were 48.33-116.5 micrograms/g between 1 hour 10 minutes and 5 hours 15 minutes after administration. Ratios of the tissue to the blood concentrations were 0.21-0.55, averaging 0.42 +/- 0.05 between 1 hour 10 minutes and 3 hours 5 minutes.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, Fujigaoka Hospital Showa University.
authors.forename: Y
authors.initials: Y
authors.lastname: Takahashi
authors.forename: O
authors.initials: O
authors.lastname: Sakurai
authors.forename: Y
authors.initials: Y
authors.lastname: Ishida
authors.forename: H
authors.initials: H
authors.lastname: Oka
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: K
authors.initials: K
authors.lastname: Narihara
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
mesh_terms: D000328:Adult; D000368:Aged; D002511:Cephalosporins / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000378:metabolism*; D005260:Female; D006801:Humans; D007420:Intestine, Large / Q000378:metabolism* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control
chemical_list: D002511:Cephalosporins; C036666:cefpiramide